The NBioP is a strategic partnership between The National Horizons Centre, CPI and FUJIFILM Diosynth Biotechnologies.
The NBioP creates a bioprocessing, biomanufacturing and biopharmaceutical hub making the North East a centre of innovation, with expertise in the full life cycle of biopharmaceuticals, from basic and applied bioprocessing research, through to biopharmaceutical scale up and ultimately, the commercial manufacture of life changing medicines.
Each organisation brings unique expertise to the partnership, with a proven track record of collaboration. The National Horizons Centre, provides the academic and skills aspect, offering industry-specific scientific expertise in basic and applied research, driving innovation, and providing workforce training and development. CPI leverages its existing industry connections, innovation facilities and expertise to reduce the risk, gain investment and accelerate the development of new biopharmaceutical products and their manufacturing processes. FUJIFILM Diosynth Biotechnologies, a global leader in the contract development and manufacture of biologics, brings its global expertise for the development of new tools and technologies for biopharmaceutical manufacturing applications. This complementary approach is truly unique, with a focus not only on industry growth but also on providing the skilled workforce of the future.
With a high-density cluster of expertise and a well-developed business ecosystem, the North East offers a bioscience community that is second to none in the UK. Access to a mature supply chain and highly-skilled work force with much lower business costs than other areas of the UK, means a start-up company can establish itself in the region for life and develop alongside the same companies that it can collaborate with throughout its business development lifecycle.
NBioP is based at Darlington's Central Park, with easy access to rail, road and air travel, the hub provides a unique location for the biopharmaceutical industry.
Darlington's Central Park is at the very heart of Darlington's life sciences offer, providing a high-quality business environment with readily available networks, support, and skills to succeed.
The Park covers 30 hectares and is the flagship regeneration project in the town, with a focussed approach to attracting biologics and pharmaceutical industries, to encourage job creation and local economic growth.
Discover - Develop - Deliver.
The National Horizons Centre (NHC) was founded in conversation with, and for the bioindustry, to discover diseases earlier, develop novel treatments, and deliver life changing medicines to those in need, quicker, safer and affordably.
The NHC, is a £22.3m biosciences research, partnerships and training facility.
The NHC has core strengths in:
CPI works with partners to translate inventions into products and processes that enhance health and wellbeing, protect and improve our environment and increase industrial productivity. As part of the High Value Manufacturing Catapult we support partners across diverse markets, such as pharmaceuticals, speciality chemicals and food and drink, through programmes that have the potential to revolutionise their businesses.
CPI has core strengths in:
FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark.
FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems.
The company offers a comprehensive list of services from cell line development using its proprietary pAVEwayTM microbial and ApolloTMX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing.
FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation.